In 2018 we started approaching thought leaders across the life sciences sector to contribute their opinions and insights and provide valuable insider knowledge to our readers. Over the past year, we have received some fascinating and enlightening outlooks from our peers with topics spanning from blockchain and AI to pharma’s role in global health. It was almost impossible to pick only 10, so head to our opinion page for more.
How Can Pharma Progress the Sustainable Development Goals?
Richard Saynor is SVP of Classic and Established Products at GSK and is responsible for driving top-line sales, leveraging the supply chain and maximising operating profit for post-patent products. In this article, he discusses Big Pharma’s responsibility to help people gain access to medicines, especially in low-income countries.
The Line Manager of Tomorrow
Ian Chamberlain provides training to help pharma salespeople talk to their customers. Here he discusses the future role of the pharmaceutical sales manager and how to approach training the tech-savvy, next generation of sales reps.
One Business or Two? The Era of Precision Medicine
The brilliant Richard Barker – founding director of New Medicine Partners, a global firm assisting public and private sector organisations accelerate the development and adoption of precision medicine – discusses the potential of this pioneering treatment and the need for a change in the relationship between biopharma and diagnostics.
M&A trends and activity in 2018
David Crean, managing director for Objective Capital Partners, a leading investment banking advisory firm examined the first half of 2018 within the life sciences sector for mergers and acquisition (M&A) and investment activities.
Thomas Cueni on Pharma’s Role to Support Universal Health Coverage
For Universal Health Coverage (UHC) day, Thomas Cueni, the director general of the IFPMA (the International Federation of Pharmaceutical Manufacturers and Associations) explains UHC and how our industry is pioneering new ways to overcome access to quality healthcare.
Thomas Cueni on Pharma’s Role to Support Universal Health Coverage
Diversity, Inclusion and Addressing Unconscious Bias
The company group chairman of Janssen’s Asia Pacific operations, Ai Hua Ong, outlines the benefits of a diverse and inclusive workforce, the correlation between diversity and innovation and the importance of addressing unconscious bias.
Blockchain & AI – Going Where it Hurts
Axel Schumacher, co-founder and chief scientific officer of Shivom, highlights Big Pharma’s tendency to be innovation-averse and the need to step out of comfort zones to adopt new technologies.
Cannabis: The Emergence of a New Paradigm in Healthcare
Mark Ware, the chief medical officer of Canopy Growth Corporation, has dedicated his career to investigating the effects of cannabinoids. Here he discusses the ‘renaissance of cannabis’ and how increased acceptance and the snowballing of regulatory changes across the globe represents a new paradigm in healthcare.
Jeopardizing US Patients’ Health Is An Unacceptable Trade-Off
Chip Davis, Jr, the president and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the holes in Trump’s pledge to provide better access to healthcare and how tariffs on generic and biosimilar medicines threaten to increase prescription drug prices and the risk of drug shortages, thereby hurting US patients.
Jeopardizing US Patients’ Health Is An Unacceptable Trade-Off
Stronger Together: Tackling the US/Canadian Opioid Epidemic
Carla Smith, previously executive VP of The Healthcare Information and Management Systems Society (HIMMS) gives us an overview of the state of the opioid crisis in Canada and the United States and explains why it is important for the two countries to come together to overcome it.
